Mesoblast (NASDAQ:MESO) Stock Price Passes Above 50-Day Moving Average – Should You Sell?

Mesoblast Limited (NASDAQ:MESO)’s share price crossed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $15.27 and traded as high as $15.73. Mesoblast shares last traded at $15.67, with a volume of 123,023 shares.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Mesoblast in a research note on Tuesday, April 21st. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold”.

Mesoblast Price Performance

The stock has a fifty day moving average of $15.27 and a two-hundred day moving average of $16.65. The stock has a market capitalization of $2.04 billion, a price-to-earnings ratio of -29.15 and a beta of 2.19. The company has a current ratio of 1.58, a quick ratio of 1.41 and a debt-to-equity ratio of 0.10.

Mesoblast (NASDAQ:MESO) last released its quarterly earnings results on Thursday, January 29th. The company reported ($0.16) earnings per share for the quarter. The company had revenue of $25.67 million during the quarter. As a group, equities research analysts forecast that Mesoblast Limited will post -0.49 earnings per share for the current year.

Insiders Place Their Bets

In other Mesoblast news, Director Gregory George purchased 2,324,072 shares of the company’s stock in a transaction that occurred on Friday, April 10th. The stock was purchased at an average cost of $1.48 per share, with a total value of $3,439,626.56. Following the acquisition, the director directly owned 8,324,072 shares of the company’s stock, valued at approximately $12,319,626.56. This trade represents a 38.73% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Over the last ninety days, insiders acquired 9,892,852 shares of company stock worth $28,429,183. Company insiders own 18.80% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Rialto Wealth Management LLC bought a new position in Mesoblast in the 4th quarter valued at $839,000. Opal Capital LLC bought a new position in Mesoblast in the 4th quarter valued at $307,000. Quadrant Capital Group LLC bought a new position in Mesoblast in the 3rd quarter valued at $113,000. Caitong International Asset Management Co. Ltd bought a new position in Mesoblast in the 4th quarter valued at $34,000. Finally, Tobias Financial Advisors Inc. boosted its position in Mesoblast by 38.3% in the 4th quarter. Tobias Financial Advisors Inc. now owns 13,828 shares of the company’s stock valued at $249,000 after buying an additional 3,828 shares during the last quarter. 1.43% of the stock is currently owned by institutional investors.

Mesoblast Company Profile

Mesoblast Limited is a global leader in allogeneic cellular medicines, focused on developing treatments for inflammatory and immunologic diseases. Founded in 2004 by Dr. Silviu Itescu, the company builds on proprietary mesenchymal lineage cell technology to create off-the-shelf, donor-derived therapies. These therapies are designed to modulate immune responses and promote tissue repair in conditions where existing medical options are limited or ineffective.

The company’s most advanced product, Alofisel® (darvadstrocel), has been approved in Europe for the treatment of complex perianal fistulas in adults with Crohn’s disease.